Original HTML
Research & Development
Advancing the science that powers next-generation radiopharmaceuticals
At Telix, R&D powers our future — strengthening our capabilities and working across the business to advance assets from discovery to clinical proof-of-concept and deliver first- and best-in-class theranostics.
From bench to bedside, the team is driving new clinical applications, workflow innovations, and manufacturing advancements to develop imaging agents and therapies that have the potential to transform how cancer is detected, monitored and treated.
Core Innovation Pillars
.
Physical Sciences
Advancing applied chemistry and physics for next-generation radiopharmaceutical development
Our Physical Sciences team advances the foundational research that enables cutting-edge radiopharmaceutical development. Through precision science and innovation, the group provides the building blocks for transformative imaging and therapeutic agents within Telix’s global pipeline.
Drug Discovery
Driving breakthroughs in cancer biology through multidisciplinary research
Our Drug Discovery team pioneers novel theranostic strategies by investigating new approaches in molecular targeting, radiobiology, and immuno-oncology. Supported by Telix Targeting Technology’s engineered antibody platform and a state-of-the-art California research facility, we are accelerating the development of next-generation radiopharmaceuticals by evaluating the best targets for each disease state.
MedTech
Advancing AI-driven imaging and surgical innovation
Our MedTech division develops technologies that enhance both precision medicine and surgical care. The SENSEI® radio-guided surgery platform and related detection technologies are extending our targeting science into the operating room to improve surgical precision and patient outcomes. We are also exploring artificial intelligence to improve imaging analysis and support better informed clinical decisions.
Non-clinical
Driving safe, compliant, and efficient drug development for global impact
Our Non-Clinical team bridges discovery and development, ensuring scientific innovation progresses safely and efficiently toward clinical and commercial outcomes. Through a combination of regulatory expertise and translational science, they guide programs through complex pathways to deliver therapies to patients worldwide, with integrity and speed.
Partnership Opportunities
We are actively exploring partnership opportunities across our R&D programs and technology platforms.
To discuss collaboration or learn more about how we can work together, please contact us.
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Telix Organizes Radiopharma R&D Into Four Pillars, Seeks Partners", "body_html": "<p><strong>California -- [CURRENT_DATE] --</strong> Telix is structuring its radiopharmaceutical research around four innovation pillars (Physical Sciences, Drug Discovery, MedTech and Non-clinical) and is actively exploring partnerships across its R&D programs and technology platforms.</p><p>The company says the R&D organization moves assets from discovery to clinical proof-of-concept, with the aim of delivering first- and best-in-class theranostics for cancer detection, monitoring and treatment.</p><h5>Drug Discovery team draws on an engineered antibody platform and a California facility</h5><p>The Drug Discovery group investigates molecular targeting, radiobiology and immuno-oncology. It is supported by Telix Targeting Technology's engineered antibody platform and a research facility in California. Its stated task is to evaluate the best target for each disease state.</p><h5>MedTech division extends targeting science into the operating room with SENSEI</h5><p>The MedTech division develops the SENSEI® radio-guided surgery platform and related detection technologies, aimed at improving surgical precision and patient outcomes. Telix is also exploring artificial intelligence for imaging analysis and clinical decision support.</p><h5>Physical Sciences and Non-clinical teams cover chemistry, physics and regulatory pathways</h5><p>The Physical Sciences team applies chemistry and physics to build the foundations of imaging and therapeutic agents in Telix's global pipeline. The Non-Clinical team links discovery to development, combining regulatory expertise and translational science to move programs toward clinical and commercial outcomes.</p><p>Telix has not disclosed financial terms, partner names or specific programs open to collaboration.</p>", "meta_description": "Telix organizes radiopharmaceutical R&D into four pillars, from drug discovery to SENSEI radio-guided surgery, and is exploring partnerships across its platforms.", "seo_keywords": "Telix, radiopharmaceuticals, theranostics, SENSEI, radio-guided surgery, drug discovery, R&D partnerships, immuno-oncology, antibody platform", "companies": ["Telix"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["general_news"], "products": ["SENSEI"], "themes": ["research_and_development", "partnerships", "theranostics"], "events": [], "cta_text": "Contact Telix to discuss R&D collaboration opportunities", "learn_more": "", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": ["Dateline city set to California (location of the research facility named in source) because no source city is given", "Removed PR language and promotional claims", "Used the [CURRENT_DATE] placeholder as instructed by the system rules"], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
da33a337d04376e5f019e2d5a743e622